Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Completed 4Terminated 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Sarcoma 1Plasma cell 1Genitourinary 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 199Breast Neoplasms 111Carcinoma, Non-Small-Cell Lung 94Triple Negative Breast Neoplasms 66Neoplasm Metastasis 44Neoplasms 42Lung Neoplasms 25Squamous Cell Carcinoma of Head and Neck 24Colorectal Neoplasms 18Stomach Neoplasms 17Esophageal Squamous Cell Carcinoma 17Adenocarcinoma 17Melanoma 15Head and Neck Neoplasms 15Ovarian Neoplasms 12Cholangiocarcinoma 11Carcinoma 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Gallbladder Neoplasms 10Esophageal Neoplasms 10Carcinoma, Pancreatic Ductal 10Small Cell Lung Carcinoma 9Sarcoma 9Fallopian Tube Neoplasms 9Biliary Tract Neoplasms 9Carcinoma, Squamous Cell 8Neoplasms by Site 7Pancreatic Diseases 6Pancreatic Adenocarcinoma 6Digestive System Neoplasms 6

Interventions

Cyclophosphamide 155Dexamethasone 141Rituximab 85fludarabine 80Lenalidomide 72Cytarabine 70Bortezomib 65fludarabine phosphate 63Gemcitabine 62venetoclax 55pomalidomide 53Etoposide 53pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recurrence × 130-nm albumin-bound paclitaxel × Clear all
NCT02945800 2026-04-02

Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
59 enrolled 11 charts
Sarcoma

Recurrence, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma

NCT06470464 2025-09-18

Thalidomide Combined With Chemotherapy in the Treatment of Relapsed or Refractory Yolk Sac Tumor

Shandong First Medical University

Phase 2 Completed
20 enrolled

Neoplasms, Germ Cell and Embryonal, Recurrence, Endodermal Sinus Tumor

NCT03989336 2024-07-15

A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer

Chinese PLA General Hospital

Phase 2 Completed
84 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

NCT01478685 2019-11-12

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Celgene

Phase 1 Completed
169 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence, Tumor Virus Infections, Carcinoma, Pancreatic Ductal

NCT02075021 2018-10-15

rev/abraxane

NYU Langone Health

Phase 1/2 Terminated
3 enrolled 3 charts
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡